Pharmalot Ed Silverman STAT Plus: Patient group asks BIO to denounce Catalyst over the $375,000 price of its rare disease drug
Pharmalot Ed Silverman STAT Plus: As pharma seeks more orphan drug designations, FDA fails to assess important needed info
